Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

Zacks
Open on Zacks
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

In the latest close session, Recursion Pharmaceuticals (RXRX) was up +2.7% at $3.80. The stock's performance was ahead of the S&P 500's daily gain of 0.7%. Elsewhere, the Dow saw an upswing of 0.28%, while the tech-heavy Nasdaq appreciated by 0.83%.

Coming into today, shares of the biotechnology company had lost 1.07% in the past month. In that same time, the Medical sector gained 3.23%, while the S&P 500 lost 1.21%.

The investment community will be closely monitoring the performance of Recursion Pharmaceuticals in its forthcoming earnings report. In that report, analysts expect Recursion Pharmaceuticals to post earnings of -$0.24 per share. This would mark year-over-year growth of 33.33%. At the same time, our most recent consensus estimate is projecting a revenue of $10.92 million, reflecting a 110.83% rise from the equivalent quarter last year.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.93 per share and a revenue of $42.82 million, representing changes of +35.42% and -42.66%, respectively, from the prior year.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Recursion Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.41% increase. Recursion Pharmaceuticals is currently a Zacks Rank #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 100, placing it within the top 41% of over 250 industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Recursion Pharmaceuticals, Inc. (RXRX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research